Journal Browser

Journal Browser

Special Issue "Emerging Neuroprotective and Regenerative Strategies for the Treatment of Demyelinating Disorders of the Central Nervous"

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Neurobiology".

Deadline for manuscript submissions: 31 January 2024 | Viewed by 79

Special Issue Editor

Special Issue Information

Dear Colleagues,

Demyelinating disorders that specifically affect the brain and/or spine in the central nervous system (CNS) are common neurological conditions and can be separated into primary and secondary idiopathic inflammatory-demyelinating diseases (IIDDs). Both groups of IIDDs are characterised by damage to the myelin sheaths covering axons, with the main difference being that in secondary IIDDs, the aetiology is usually well defined (e.g., post-infectious, ischemic, metabolic, or toxic), so therapies targeting the underlying cause can (in most cases) successfully reverse disease progression. In contrast, there is no known cause for primary IIDDs, although growing evidence suggests the contribution of several risk factors (i.e., genetics, environment, life style, diet, etc.) in disease pathogenesis. To date, there is no definitive cure for primary IIDDs; however, there are several disease-modifying therapies able to alter disease progression in some patients and an increasing number of promising therapeutic strategies are currently under scrutiny in preclinical models and in clinical trials. Such emerging therapeutics primarily aim to increase neuroprotection, enhance nerve conduction and/or promote myelin regeneration.

The main scope of the Special Issue is to shed light on the most recent advances on such novel therapeutic strategies for IIDDs, as well as rare demyelinating conditions of the CNS. Special emphasis will be given to contributions focusing on the identification and preclinical validation of targets of potential clinical significance in demyelinating disorders of the CNS, as well as review articles providing updates on emerging treatment options for such devastating pathologies.

Dr. Alessandro Castorina
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • neuroprotection
  • demyelinating disorders
  • multiple sclerosis
  • optic neuritis
  • transverse myelitis
  • Aicardi–Goutières syndrome
  • acute disseminated encephalomyelitis
  • neuromyelitis optica
  • HTLV-I associated myelopathy
  • Balo’s disease
  • Schilder’s disease

Published Papers

This special issue is now open for submission.
Back to TopTop